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Natural killer (NK) cells are innate lymphocytes that are capable of eliminating tumor
cells and are therefore used for cancer therapy. Although many early investigators used
autologous NK cells, including lymphokine-activated killer cells, the clinical efficacies were
not satisfactory. Meanwhile, human leukocyte antigen (HLA)-haploidentical hematopoietic
stem cell transplantation revealed the antitumor effect of allogeneic NK cells, and HLA-
haploidentical, killer cell immunoglobulin-like receptor ligand-mismatched allogeneic NK
cells are currently used for many protocols requiring NK cells. Moreover, allogeneic NK
cells from non-HLA-related healthy donors have been recently used in cancer therapy.
The use of allogeneic NK cells from non-HLA-related healthy donors allows the selection
of donor NK cells with higher flexibility and to prepare expanded, cryopreserved NK cells
for instant administration without delay for ex vivo expansion. In cancer therapy with
allogeneic NK cells, optimal matching of donors and recipients is important to maximize
the efficacy of the therapy. In this review, we summarize the present state of allogeneic
NK cell therapy and its future directions.
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Introduction
Cancer is amajor threat for humansworldwide, with approximately 14million new cases and 8.2mil-
lion cancer-related deaths in 2012 (1). Although most common cancer treatments include surgery,
chemotherapy, and radiotherapy, unsatisfactory cure rates require new therapeutic approaches,
especially for refractory cancers. For this purpose, cancer immunotherapies with various cytokines,
antibodies, and immune cells have been clinically applied to patients to encourage their own immune
system to help fight the cancer (2).
Adoptive cellular immunotherapies have employed several types of immune cells, including
dendritic cells (DCs), cytotoxic T lymphocytes (CTLs), lymphokine-activated killer (LAK) cells,
cytokine-induced killer (CIK) cells, and natural killer (NK) cells. Although there has been recent
progress in DC therapy and CTL therapy, clinical applications are somewhat limited because cancer
antigens must first be characterized and autologous cells must be used. By contrast, LAK cells, CIK
cells, and NK cells have antigen-independent cytolytic activity against tumor cells. In particular,
NK cells can be used from not only autologous sources but also allogeneic sources and, recently,
allogeneic NK cells have been employed more often in cancer treatment. Whereas autologous NK
cells from cancer patients may have functional defects (3), allogeneic NK cells from healthy donors
have normal function and can be safely administered to cancer patients (4). Allogeneic NK cell
therapy is particularly beneficial because it can enhance the anti-cancer efficacy of NK cells via
donor–recipient incompatibility in terms of killer cell immunoglobulin-like receptors (KIRs) on
donor NK cells and major histocompatibility complex (MHC) class I on recipient tissues.
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Biology of NK Cells and Their Receptors
Natural killer cells are innate lymphocytes that provide a first line
of defense against viral infections and cancer (5). HumanNK cells
are recognized as CD3 CD56+ lymphocytes. They can be further
subdivided into two subsets based on the surface expression level
of CD56. The CD56dim population with low-density expression
of CD56 comprises approximately 90% of human blood NK
cells and has a potent cytotoxic function, whereas the CD56bright
population (approximately 10% of blood NK cells) with high-
density expression of CD56 displays a potent cytokine producing
capacity and has immunoregulatory functions (6). The CD56dim
NK cell subset also expresses high levels of the Fc receptor for
IgG (FcγRIII, CD16), which allows them to mediate antibody-
dependent cellular cytotoxicity (ADCC) (7). NK cells comprise
5–15%of circulating lymphocytes and are also found in peripheral
tissues, including the liver, peritoneal cavity, and placenta. Acti-
vated NK cells are capable of extravasation and infiltration into
tissues that contain pathogens or malignant cells while resting NK
cells circulate in the blood (8).
The NK cell activity is regulated by signals from activating
and inhibitory receptors (9, 10). The activating signal is mediated
by several NK receptors including NKG2D and natural cytotox-
icity receptors (NCRs) (9–11). By contrast, NK cell activity is
suppressed by inhibitory receptors, including KIRs, which bind
to human leukocyte antigen (HLA) class I molecules on target
cells (9, 10, 12). NKG2A is also an important inhibitory receptor
binding to non-classical HLAmolecule, HLA-E (13). If target cells
lose or downregulate HLA expression (14), the NK inhibitory
signal is abrogated, allowing NK cells to become activated and
kill malignant targets. However, NK cell function is impaired
in cancer patients by various mechanisms, particularly in tumor
microenvironment (15).
Although NK cell activity is determined by the summa-
tion of signals from activating and inhibitory receptors, the
inhibitory signal through KIRs is a main regulator of NK cell
function particularly in allogeneic settings. Inhibitory KIRs have
long cytoplasmic tails containing two immunoreceptor tyrosine-
based inhibition motifs (ITIMs). Each KIR has its cognate lig-
and and consists of two (KIR2DL) or three (KIR3DL) extra-
cellular Ig-domains. KIR2DL1 and KIR2DL2/3 recognize group
2 HLA-C (called C2, Lys80) and group 1 HLA-C (called C1,
Asn80), respectively. KIR3DL1 recognizes HLA-Bw4 (16). The
KIR repertoire on human NK cells is randomly determined
and independent of the number and allotype of HLA class I
ligands (17).
Therapeutic Efficacy of Allogeneic NK Cells
Role of Allogeneic NK Cells in Hematopoietic
Stem Cell Transplantation
The antitumor activity of allogeneic NK cells has been demon-
strated in the setting of hematopoietic stem cell transplantation
(HSCT). Allogeneic HSCT is an established curative treatment
for hematologic malignancies. In allogeneic HSCT, donor T cells
contribute to graft-versus-host disease (GVHD) and graft-versus-
tumor (GVT) effects (18). In T cell-depleted HSCT, however,
donor NK cells are the major effector cells responsible for con-
trolling residual cancer cells before T cell reconstitution (19, 20).
Natural killer cells are the first lymphoid population to recover
after allogeneic HSCT. In the first month of transplantation,
reconstituted NK cells represent the predominant lymphoid cells
and play a crucial role in controlling the host immune system.
Allogeneic NK cells prevent viral infections and restrain residual
cancer cells in the early phase of transplantation (21). Of note,
the GVT activity of donor NK cells is significantly improved
when KIRs of donor and HLA class I of the recipient are incom-
patible, and consequently when inhibitory signals are absent, as
observed in HLA-haploidentical HSCT (22). Therefore, increased
GVT activity of NK cells with KIR-HLA incompatibility is the
underlying rationale for the development of allogeneic NK cell
therapy.
Allogeneic NK Cell-Based Immunotherapy
Following the discovery of inhibitory KIRs and the understanding
that they play a role in preventingNK cell killing of selfMHC class
I-expressing tumor cells, investigators began to research the pos-
sibility of using allogeneic donor NK cells instead of autologous
NK cells for cancer therapy. Several groups have infused activated,
expanded donor NK cells to patients early after allogeneic HSCT
to provide antitumor effects (23). In Table 1, clinical trials with
allogeneic NK cells as therapeutics are summarized.
Allogeneic NK cells can be delivered either in a setting of HSCT
or a non-HSCT setting. HSCT is a curative platform for many
patients with hematologic malignancies. For patients lacking an
HLA-identical donor and for those with progressive disease, the
use of HLA-haploidentical family donors is increasingly consid-
ered to be a suitable alternative. Therefore, in most clinical trials
using allogeneic NK cells, autologous or haploidentical HSCT are
followed by NK cell infusion as therapeutics to protect relapse and
delay recurrence. Several groups have explored the use of allo-
geneic NK cells in treating relapses of hematologic malignancies
following HLA-haploidentical HSCT in clinical trials, and GVHD
did not develop when allogeneic haploidentical NK cells were
used (19, 24). In these studies, tumor responses were observed in
some patients and overall rates of relapse were reduced. Notably,
infusion of allogeneic NK cells can cause cancer regression even
without allogeneic HSCT. The patients received allogeneic NK
cells without HSCT following non-myeloablative chemotherapy.
The chemotherapy pre-conditioning delayed the rejection of the
transferred cells, and in some cases, the allogeneic NK population
even expanded before being ultimately rejected (25, 26).
In a non-transplantation setting,Miller and colleagues were the
first to establish the safety and efficacy of adoptive cellular transfer
of HLA-haploidentical NK cells in patients with advanced cancer
(27). In this study, 19 acutemyeloid leukemia (AML) patients were
given haploidentical NK cell infusions together with IL-2 and 5
patients achieved complete remission. Allogeneic NK cells with
KIR-HLA mismatches between patients and donors exhibited
greater tumor-killing activity without causing GVHD. Based on
the success observed in AML, a number of clinical trials are being
carried out to determine the feasibility and efficacy of allogeneic
NK cell infusion for cancer treatment. Many of 15 ongoing clin-
ical trials are oriented to hematological malignancies including
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TABLE 1 | Selected clinical trials with expanded allogeneic NK cells.
Diseases Status Phase of
trials
Cell product Combined therapy Institute ClinicalTrials.gov
Identifier
Hepatocellular carcinoma Ongoing Phase 2 Ex vivo-expanded NK
cells
None Samsung Medical Center,
Korea
NCT02008929
Lymphoma and solid
tumors
Completed Phase 1 Ex vivo-expanded NK
cells
None Seoul National University
Hospital, Korea
NCT01212341
High-risk solid tumors Ongoing Phase 2 Ex vivo-expanded NK
cells
Haploidentical HSCT,
RIC, and IL-2
Samsung Medical Center,
Korea
NCT01807468
Non-B lineage hematologic
malignancies and solid
tumors
Completed Phase 1 Ex vivo-expanded
haploidentical NK cells
Chemotherapy and
IL-2
St. Jude Children’s Research
Hospital, USA
NCT00640796
Hematological malignancies Ongoing Phase 1 IL-2-activated NK cells Haploidentical HSCT
and RIC
Institut Paoli-Calmettes,
France
NCT01853358
Multiple myeloma Ongoing Phase 1/2 Ex vivo-expanded
haploidentical NK cells
Autologous HSCT
and chemotherapy
University Hospital, Basel,
Switzerland
NCT01040026
Leukemia and
myeloproliferative disease
Ongoing Phase 1/2 Ex vivo-expanded NK
cells
Haploidentical HSCT,
TBI, and
chemotherapy
M.D. Anderson Cancer
Center, USA
NCT01904136
ALL Ongoing Phase 2 K562-mb15-41BBL
and IL-2-stimulated NK
cells
Haploidentical HSCT
and chemotherapy
National University Health
System, Singapore
NCT01974479
AML and ALL Ongoing Phase 1/2 Ex vivo-expanded NK
cells
Haploidentical HSCT Asan Medical Center, Korea NCT01795378
Relapsed/refractory
pediatric acute leukemia
Ongoing Phase 2 Activated and
expanded NK cells
Haploidentical HSCT
and salvage
chemotherapy
Hospital Universitario La Paz,
Spain
NCT02074657
Myelodysplastic syndrome
and leukemia
Completed Phase 1/2 IL-2-activated NK cells Haploidentical HSCT,
chemotherapy, and
IL-2
M.D. Anderson Cancer
Center, USA
NCT00402558
Leukemia Completed Phase 2 IL-2-activated NK cells Chemotherapy and
IL-2
Masonic Cancer Center,
University of Minnesota, USA
NCT00274846
Relapsed/refractory
pediatric T cell leukemia and
lymphoma
Ongoing Phase 1/2 Activated and
expanded NK cells
Salvage
chemotherapy
Hospital Infantil Universitario
Niño Jesús, Madrid, Spain
NCT01944982
Leukemia Ongoing Phase 1/2 mbIL21-expanded
haploidentical NK cells
Chemotherapy M.D. Anderson Cancer
Center, USA
NCT01787474
Acute leukemia and
myelodysplastic syndrome
Ongoing Phase 1 K562-mb15-41BBL
and IL-2-stimulated NK
cells
Immunosuppressive
therapy and IL-2
National University Hospital,
Singapore
NCT02123836
HSCT, hematopoietic stem cell transplantation; RIC, reduced-intensity conditioning; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; TBI, total body irradiation.
leukemia, multiple myeloma, and myelodysplastic/proliferative
diseases. Additionally, clinical trials have shown that allogeneic
NK cells play a therapeutic role in solid tumors (26, 28, 29). The
clinical efficacy of expanded allogeneic NK cells was investigated
in patients with recurrent metastatic breast and ovarian cancers in
combinationwith aHi-Cy/Flu preparative chemotherapy regimen
(29). Adoptive transfer of ex vivo-expanded allogeneic NK cells
was safe and effective in patients with advanced non-small cell
lung cancer (26). These findings provided proof of concept that
allogeneic NK cells could be effective not only in hematologic
malignancy patients but also in solid tumor patients. Clinical
trials are currently carried out in hepatocellular carcinoma and
neuroblastoma (NCT02008929, NCT01807468).
Adoptive transfer of allogeneicNKcells that come froma totally
unrelated donor has also been demonstrated to be safe without
any significant side effects (NCT01212341). Allogeneic NK cell
therapy is currently applied to patients with advanced hepatocel-
lular carcinoma after curative resection (NCT02008929). In this
clinical trial, ex vivo-expanded allogeneic NK cells were admin-
istered without combination with other therapeutic modalities to
investigate the isolated effect of infused allogeneic NK cells.
Taken together, the clinical studies mentioned above demon-
strated that the infusion of allogeneic NK cells after ex vivo
expansion is largely safe and some responses appear encouraging.
Optimized Selection of Donors
Lessons from Allogeneic HSCT
In T cell-depleted HSCT, donor NK cells are the major effector
cells responsible for controlling residual cancer cells (19), and
it has been shown that the KIR genotype of donors influences
the outcome of HSCT (30). From the experience of allogeneic
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HSCT, we can learn how allogeneic NK cell donors are selected
to maximize the antitumor activity of infused allogeneic NK cells.
There are two distinct types of KIR haplotypes: group A and
groupB. TheKIR group B haplotype hasmore activating receptors
than the KIR group A haplotype (31). According to the KIR
genotype, all individuals can be divided into the A/A genotype
(homozygous for A haplotypes) or the B/x genotype (having
1 or 2 B haplotypes). There have been reports that the donor
KIR genotype influences outcomes of unrelated HSCT for acute
hematological malignancies and that the B/x genotype confers
significant survival benefit to patients (22, 32, 33). B/x donors
are further differentiated on whether their B haplotype genes are
in the centromeric or/and telomeric part. On the basis of this
information, the KIR B-content score can be calculated from 0 to
4 (30, 34). High donor KIR B-content scores have been associated
with a significantly reduced relapse in children after haploidenti-
cal HSCT for acute lymphocytic leukemia (ALL) (35), and donors
with two or more B-content scores showed superior survival after
unrelated HSCT for AML (27).
Incompatibility betweenKIRs of donors andHLAs of recipients
is also an important factor. Considering that each KIR binds to
specific HLA allotypes as an inhibitory ligand (e.g., KIR2DL1 to
group 2 HLA-C, KIR2DL2/3 to group 1 HLA-C, and KIR3DL1
to HLA-Bw4), a recipient may lack specific HLA allotypes that
inhibit donor NK cells. In this case, higher antitumor activity of
donor NK cells is expected. Indeed, antitumor activity of donor
NK cells is significantly improved when KIRs and HLAs are
incompatible between donor and recipient (19, 24, 36).
In addition to the KIR genotype and incompatibility, actual
expression of KIRs on NK cells needs to be considered for the
best antitumor activity of allogeneic NK cells because the expres-
sion of KIRs occurs in stochastic combination (37). Antitumor
activity is likely to be mediated by single-KIR+ allogeneic NK
cells not encountering any inhibitory signal from HLA molecules
on recipient cells (38). Although NK cells are the first lymphoid
population to recover after allogeneic HSCT (21), reconstitution
of mature NK receptor repertoires requires at least 3months (39).
Importantly, during this period, donor-derived single-KIR+ NK
cells are not fully functional (38). In this aspect, infusion of single-
KIR+ mature NK cells selected for KIR-HLA mismatches might
lead to better clinical outcomes. Currently, multicolor flow cytom-
etry enables the examination of KIR expression in the NK cell
population. The approach to generate GMP-grade single-KIR+
NK cells (40) will allow customized allogeneic NK cell therapy.
Sources of Allogeneic NK Cells
To permit therapeutic use of allogeneic NK cells in clinical set-
tings, a sufficient number of highly enriched NK cells must be
obtained. The sources for allogeneic NK cells include periph-
eral blood mononuclear cells (PBMCs) collected by leukapheresis
from healthy donors and umbilical cord blood (UCB).
Peripheral blood mononuclear cells collected by leukapheresis
are generally utilized as a source of allogeneic NK cells. Vari-
ous methods to obtain ex vivo-expanded, activated, and CD3+
T cell-depleted NK cells have been well established in clinical
scales and grades (41). Although those NK cells showed potent
antitumor efficacy in vitro and in vivo, clinical outcomes were
insufficient. The clinical resultsmight be influenced by several fac-
tors including malignancy types and pre-conditioning treatment.
As described above, the therapeutic efficacy of allogeneic NK cell
therapy can be potentiated by optimal selection of NK cell donors
in a non-HSCT setting. Since NK cells from haploidentical donors
had been used in allogeneic HSCT settings, allogeneic NK cells
were mostly obtained from haploidentical donors even in a non-
HSCT setting. Recently, ex vivo-expanded, allogeneic NK cells
from unrelated, random donors were successfully administered to
patients with malignant lymphoma or advanced solid tumors in a
phase 1 trial (NCT01212341) that has proceeded to a phase 2 trial
of patients with hepatocellular carcinoma (NCT02008929). This
strategy, which used unrelated NK donors, allowed free selection
of the best donor in terms of donor KIR-recipient HLA incom-
patibility without limitation of small pools of related donors. Fur-
thermore, the use of allogeneic NK cells from non-HLA-related
healthy donors allows preparation of expanded, cryopreserved
NK cells for instant administration without delay for ex vivo
expansion.
Umbilical cord blood is another promising source of allogeneic
NK cells. However, cytokine-based differentiation of CD34+
hematopoietic stem and progenitor cells to NK cells needs to be
carried out to obtain large numbers of functional NK cells from
UCB (42). This process requires high-dose cytokine cocktails and
delicate culture regimens that may result in low-cost effective-
ness. Recently, an NK cell expansion method from UCB using
artificial antigen presenting feeder cells was reported. NK cells
expanded by this method showed in vitro cytotoxicity against
various myeloma targets and in vivo antitumor activity in a mouse
model of myeloma (43).
Future Directions
Genetic Modification
Genetic modification is a promising option for redirecting the
function of various types of immune cells (44). Much work has
been performed, particularly on genetically redirecting T cells
against a range of tumor antigens. For example, T cells expressing
chimeric antigen receptors (CARs) targeting CD19 antigens have
been developed to treat B-cell-derived malignancy, and clinical
trials are currently ongoing (45–47). The successful experience
with CAR-expressing T cells in the treatment of hematological
malignancies has prompted the development of CAR-expressing
NK cells. NK cells are attractive for CAR expression because they
have cytotoxic function and, unlike T cells, allogeneic NK cells do
not cause GVHD.
As summarized in Table 2, two clinical trials are investigating
the use of CAR-expressing allogeneic NK cells. The aim of both
studies is to assess the safety, feasibility, and efficacy of expanded,
activated, and CD19-redirected haploidentical NK cells in ALL
patients who have persistent disease after intensive chemotherapy
or HSCT (NCT00995137, NCT01974479). Further, other tumor
antigens, such as CS1, CEA, CD138, and CD33, are targeted by
CARs expressed by NK cells, although NK-92, YT, or NKL cell
lines were used (48–51).
Genetic modification is also performed to express cytokine
transgenes in NK cells. NK cell function could be enhanced by
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TABLE 2 | Genetically modified, expanded allogeneic NK cells.
Modification Genes
transferred
NK cells Application Status Reference/ClinicalTrials.gov Identifier
Target specificity CD19 Haploidentical, expanded
NK cells
ALL Phase 1 St. Jude Children’s Research Hospital
(NCT00995137)
CD19 Haploidentical, expanded
NK cells
ALL Phase 2 National University Health System,
Singapore (NCT01974479)
CD19 Expanded NK cells B-ALL Preclinical Cho et al. (52)
CD20 Expanded NK cells CD20+ B-NHL Preclinical Chu et al. (53)
GD2 Expanded NK cells Neuroblastoma Preclinical Esser et al. (54)
NK cell function NKG2D Expanded NK cells Various tumor targets (B-ALL etc.) Preclinical Chang et al. (55)
IL-12 IL-2-activated NK cells B16 lung tumor Preclinical Goding et al. (56)
ALL, acute lymphocytic leukemia; B-NHL, B-cell non-Hodgkin lymphoma; B-ALL, B-cell acute lymphoblastic leukemia.
expression of cytokines, such as IL-2 (57, 58), IL-12 (56, 59), and
IL-15 (60–62). Cytokine expression enhances the activation of NK
cells, survival and proliferation of NK cells, and accumulation
of NK cells in tumor tissues. To improve the efficacy of NK cell
therapy, genetic modification of NK cells is explored to express
activating receptors, such as NKG2D (55).
Therapeutic Regimens
In allogeneic NK cell therapy, optimal therapeutic regimens
for clinical applications should be considered because adop-
tively transferred NK cells not only target tumor cells but also
interact with the immunological environment. To potentiate the
therapeutic efficacy of allogeneic NK cells, proper strategies,
including pre-conditioning or combination therapy, could be
applied (34).
Upregulation of NKG2D ligands by spironolactone (63) or his-
tone deacetylase inhibitors (64, 65) and upregulation of TRAIL-R2
by doxorubicin (66) result in enhanced antitumor efficacy of NK
cells. Proteasome inhibitors also sensitize tumor cells to NK cell-
mediated killing via TRAIL and FasL pathways. In addition, c-kit
tyrosine kinase inhibitor (67) and JAK inhibitors (68) increase
the susceptibility of tumor cells to NK cytotoxicity and enhance
antitumor responses by increased IFN-γ production from NK
cells. However, protein kinase inhibitors should be used cautiously
because some protein kinase inhibitors, such as sorafenib, inhibit
the effector function of NK cells (69).
Immunomodulatory drugs can augment NK cell function.
Lenalidomide enhances rituximab-induced killing of non-
Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemia
through NK cell and monocyte-mediated ADCC mechanisms
(70). Combination therapy using IL-2 and anti-CD25 shows
anti-leukemic effects by depletion of regulatory T cells in addition
to activation and expansion of NK cells (71). Alloferon, an
immunomodulatory peptide, enhances the expression of NK-
activating receptor 2B4 and granule exocytosis from NK cells
against cancer cells (72).
Therapeutic antibodies can be combined with allogeneic NK
cell therapy (73). Antibodies against tumor antigens (e.g., CD20
and CS1) can induce ADCC of NK cells (74, 75). Antibodies to
activating NK receptors (e.g., 4-1BB, GITR, NKG2D, DNAM-1,
and NCRs) can enhance NK activation (74, 76–79). In addition,
inhibitory receptors (e.g., KIR2DL, PD-1, PD-L1, and NKG2A)
can be blocked by antibodies (80–85). Bispecific and trispecific
killer cell engagers directly activateNK cells throughCD16 signal-
ing and thus, induce cytotoxicity and cytokine production against
tumor targets (86, 87).
Conclusion
Antitumor activity of allogeneic NK cells was first observed in
a setting of HLA-haploidentical HSCT. Allogeneic NK cell ther-
apy was tried mostly using HLA-haploidentical NK cells with
or without allogeneic HSCT and, recently, allogeneic NK cells
from unrelated, random donors have been used in a non-HSCT
setting. The efficacy of allogeneicNK cell therapy can be enhanced
by optimal donor selection in terms of the KIR genotype of
donors and donor KIR-recipient MHC incompatibility. Further-
more, efficacy can be increased by geneticmodification ofNKcells
and optimized therapeutic regimens. In the future, allogeneic NK
cell therapy can be an effective therapeutic modality for cancer
treatment.
References
1. Stewart BW, Wild CP. World Cancer Report 2014. Lyon: IARC Press, Interna-
tional Agency for Research on Cancer (2014).
2. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies
in cancer treatment.Nat Rev Cancer (2012) 12(4):237–51. doi:10.1038/nrc3237
3. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-
directed therapies: moving from unexpected results to successful strategies.Nat
Immunol (2008) 9(5):486–94. doi:10.1038/ni1580
4. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current
insights and future prospects. J Intern Med (2009) 266(2):154–81. doi:10.1111/
j.1365-2796.2009.02121.x
5. Martinet L, Smyth MJ. Balancing natural killer cell activation through paired
receptors. Nat Rev Immunol (2015) 15(4):243–54. doi:10.1038/nri3799
6. Ljunggren H-G, Malmberg K-J. Prospects for the use of NK cells in
immunotherapy of human cancer.Nat Rev Immunol (2007) 7(5):329–39. doi:10.
1038/nri2073
7. Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-
dependent cell-mediated cytotoxicity. J Biomed Biotechnol (2011) 2011:379123.
doi:10.1155/2011/379123
8. Vivier E, Tomasello E, BaratinM,Walzer T, Ugolini S. Functions of natural killer
cells. Nat Immunol (2008) 9(5):503–10. doi:10.1038/ni1582
9. Lanier LL. NK cell recognition. Annu Rev Immunol (2005) 23:225–74. doi:10.
1146/annurev.immunol.23.021704.115526
Frontiers in Immunology | www.frontiersin.org June 2015 | Volume 6 | Article 2865
Lim et al. Allogeneic NK cell therapy
10. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling NK
cell responses: integration of signals for activation and inhibition. Annu Rev
Immunol (2013) 31:227–58. doi:10.1146/annurev-immunol-020711-075005
11. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al.
Activating receptors and coreceptors involved in human natural killer cell-
mediated cytolysis. Annu Rev Immunol (2001) 19(1):197–223. doi:10.1146/
annurev.immunol.19.1.197
12. Long EO. Regulation of immune responses through inhibitory receptors. Annu
Rev Immunol (1999) 17(1):875–904. doi:10.1146/annurev.immunol.17.1.875
13. Braud VM, Allan DS, O’Callaghan CA, Söderström K, D’Andrea A, Ogg GS,
et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
Nature (1998) 391(6669):795–9. doi:10.1038/35869
14. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors
from T-cell recognition: molecular mechanisms and functional significance.
Adv Immunol (2000) 74:181–273. doi:10.1016/S0065-2776(08)60911-6
15. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P,
et al. Profound coordinated alterations of intratumoral NK cell phenotype and
function in lung carcinoma. Cancer Res (2011) 71(16):5412–22. doi:10.1158/
0008-5472.CAN-10-4179
16. Thielens A, Vivier E, Romagné F. NK cell MHC class I specific receptors (KIR):
from biology to clinical intervention. Curr Opin Immunol (2012) 24(2):239–45.
doi:10.1016/j.coi.2012.01.001
17. Shilling HG, Young N, Guethlein LA, Cheng NW, Gardiner CM, Tyan D, et al.
Genetic control of human NK cell repertoire. J Immunol (2002) 169(1):239–47.
doi:10.4049/jimmunol.169.1.239
18. Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow
transplantation across minor histocompatibility barriers in mice. Prevention
by removing mature T cells from marrow. J Exp Med (1978) 148(6):1687–98.
doi:10.1084/jem.148.6.1687
19. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A,
et al. Effectiveness of donor natural killer cell alloreactivity in mismatched
hematopoietic transplants. Science (2002) 295(5562):2097–100. doi:10.1126/
science.1068440
20. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M,
et al. HLA-C-dependent prevention of leukemia relapse by donor activating
KIR2DS1. N Engl J Med (2012) 367(9):805–16. doi:10.1056/NEJMoa1200503
21. Wu CJ, Ritz J. Induction of tumor immunity following allogeneic stem cell
transplantation. Adv Immunol (2006) 90:133–73. doi:10.1016/S0065-2776(06)
90004-2
22. Impola U, Turpeinen H, Alakulppi N, Linjama T, Volin L, Niittyvuopio R,
et al. Donor haplotype B of NK KIR receptor reduces the relapse risk in HLA-
identical sibling hematopoietic stem cell transplantation of AML patients. Front
Immunol (2014) 5:405. doi:10.3389/fimmu.2014.00405
23. Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable
human NK cells for the immunotherapy of cancer. Scientifica (2014)
2014:205796. doi:10.1155/2014/205796
24. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. Donor
natural killer cell allorecognition ofmissing self in haploidentical hematopoietic
transplantation for acute myeloid leukemia: challenging its predictive value.
Blood (2007) 110(1):433–40. doi:10.1182/blood-2006-07-038687
25. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: a
pilot study to determine the safety and feasibility of haploidentical natural killer
cell transplantation in childhood acute myeloid leukemia. J Clin Oncol (2010)
28(6):955–9. doi:10.1200/JCO.2009.24.4590
26. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A,
Baxevanis CN, et al. A phase I trial of adoptive transfer of allogeneic natu-
ral killer cells in patients with advanced non-small cell lung cancer. Cancer
Immunol Immunother (2010) 59(12):1781–9. doi:10.1007/s00262-010-0904-3
27. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch
SK, et al. Successful adoptive transfer and in vivo expansion of human hap-
loidentical NK cells in patients with cancer. Blood (2005) 105(8):3051–7. doi:10.
1182/blood-2004-07-2974
28. Re F, Staudacher C, Zamai L, Vecchio V, Bregni M. Killer cell Ig-like receptors
ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors.
Cancer (2006) 107(3):640–8. doi:10.1002/cncr.22002
29. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A
phase II study of allogeneic natural killer cell therapy to treat patients with
recurrent ovarian and breast cancer. Cytotherapy (2011) 13(1):98–107. doi:10.
3109/14653249.2010.515582
30. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, et al.
Donor selection for natural killer cell receptor genes leads to superior survival
after unrelated transplantation for acute myelogenous leukemia. Blood (2010)
116(14):2411–9. doi:10.1182/blood-2010-05-283051
31. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K,
Corliss B, et al. Human diversity in killer cell inhibitory receptor genes.
Immunity (1997) 7(6):753–63. doi:10.1016/S1074-7613(00)80394-5
32. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, et al.
Donors with group B KIR haplotypes improve relapse-free survival after unre-
lated hematopoietic cell transplantation for acute myelogenous leukemia. Blood
(2009) 113(3):726–32. doi:10.1182/blood-2008-07-171926
33. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ. Improved
survivalwith inhibitory killer immunoglobulin receptor (KIR) genemismatches
and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone
marrow transplantation. Biol Blood Marrow Transplant (2010) 16(4):533–42.
doi:10.1016/j.bbmt.2009.11.022
34. Leung W. Infusions of allogeneic natural killer cells as cancer therapy. Clin
Cancer Res (2014) 20(13):3390–400. doi:10.1158/1078-0432.CCR-13-1766
35. Oevermann L, Michaelis SU, Mezger M, Lang P, Toporski J, Bertaina A, et al.
KIR B haplotype donors confer a reduced risk for relapse after haploidentical
transplantation in children with ALL. Blood (2014) 124(17):2744. doi:10.1182/
blood-2014-03-565069
36. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A. Exploitation of
alloreactive NK cells in adoptive immunotherapy of cancer.Curr Opin Immunol
(2005) 17(2):211–7. doi:10.1016/j.coi.2005.01.007
37. Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS, et al.
Comparison of killer Ig-like receptor genotyping and phenotyping for selection
of allogeneic blood stem cell donors. J Immunol (2005) 174(10):6540–5. doi:10.
4049/jimmunol.174.10.6540
38. Vago L, Forno B, Sormani MP, Crocchiolo R, Zino E, Di Terlizzi S, et al.
Temporal, quantitative, and functional characteristics of single-KIR-positive
alloreactive natural killer cell recovery account for impaired graft-versus-
leukemia activity after haploidentical hematopoietic stem cell transplantation.
Blood (2008) 112(8):3488–99. doi:10.1182/blood-2007-07-103325
39. Tanaka J, Mori A, Ohta S, Yamamoto Y, Kobayashi S, Hashino S, et al.
Expression of HLA-C-specific natural killer cell receptors (CD158a and
CD158b) on peripheral blood mononuclear cells after allogeneic bone marrow
transplantation. Br J Haematol (2000) 108(4):778–83. doi:10.1046/j.1365-2141.
2000.01938.x
40. Siegler U, Meyer-Monard S, Jörger S, Stern M, Tichelli A, Gratwohl A, et al.
Good manufacturing practice-compliant cell sorting and large-scale expan-
sion of single KIR-positive alloreactive human natural killer cells for multiple
infusions to leukemia patients. Cytotherapy (2010) 12(6):750–63. doi:10.3109/
14653241003786155
41. Koepsell SA, Miller JS, McKenna DH Jr. Natural killer cells: a review of man-
ufacturing and clinical utility. Transfusion (2013) 53(2):404–10. doi:10.1111/j.
1537-2995.2012.03724.x
42. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, DeWitte T, et al.
Clinical-grade generation of active NK cells from cord blood hematopoietic
progenitor cells for immunotherapy using a closed-system culture process.PLoS
One (2011) 6(6):e20740. doi:10.1371/journal.pone.0020740
43. Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, et al. Antigen
presenting cell-mediated expansion of human umbilical cord blood yields log-
scale expansion of natural killer cells with anti-myeloma activity. PLoS One
(2013) 8(10):e76781. doi:10.1371/journal.pone.0076781
44. Pegram HJ, Kershaw MH, Darcy PK. Genetic modification of natural killer
cells for adoptive cellular immunotherapy. Immunotherapy (2009) 1(4):623–30.
doi:10.2217/imt.09.36
45. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al.
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N
Engl J Med (2013) 368(16):1509–18. doi:10.1056/NEJMoa1215134
46. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric
antigen receptor T cells for sustained remissions in leukemia. N Engl J Med
(2014) 371(16):1507–17. doi:10.1056/NEJMoa1407222
47. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feld-
man SA, et al. T cells expressing CD19 chimeric antigen receptors for acute
lymphoblastic leukaemia in children and young adults: a phase 1 dose-
escalation trial. Lancet (2015) 385(9967):517–28. doi:10.1016/S0140-6736(14)
61403-3
Frontiers in Immunology | www.frontiersin.org June 2015 | Volume 6 | Article 2866
Lim et al. Allogeneic NK cell therapy
48. Chu J, Deng Y, Benson D, He S, Hughes T, Zhang J, et al. CS1-specific chimeric
antigen receptor (CAR)-engineered natural killer cells enhance in vitro and
in vivo antitumor activity against human multiple myeloma. Leukemia (2014)
28(4):917–27. doi:10.1038/leu.2013.279
49. Schirrmann T, Pecher G. Human natural killer cell line modified with
a chimeric immunoglobulin T-cell receptor gene leads to tumor growth
inhibition in vivo. Cancer Gene Ther (2002) 9(4):390–8. doi:10.1038/sj.cgt.
7700453
50. Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, et al. Transfection of
chimeric anti-CD138 gene enhances natural killer cell activation and killing of
multiple myeloma cells.Mol Oncol (2014) 8(2):297–310. doi:10.1016/j.molonc.
2013.12.001
51. SchirrmannT, Pecher G. Specific targeting of CD33+ leukemia cells by a natural
killer cell line modified with a chimeric receptor. Leuk Res (2005) 29(3):301–6.
doi:10.1016/j.leukres.2004.07.005
52. Cho F-N, Chang T-H, Shu C-W, Ko M-C, Liao S-K, Wu K-H, et al. Enhanced
cytotoxicity of natural killer cells following the acquisition of chimeric antigen
receptors through trogocytosis. PLoS One (2014) 9(10):e109352. doi:10.1371/
journal.pone.0109352
53. Chu Y, Hochberg J, Yahr A, Ayello J, van de Ven C, Barth MJ, et al. Targeting
CD20+ aggressive B-cell non-hodgkin lymphoma by anti-CD20 CAR mRNA
modified expanded natural killer cells in vitro and in NSG mice. Cancer
Immunol Res (2014) 3(4):333–44. doi:10.1158/2326-6066.CIR-14-0114
54. Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, et al. NK cells
engineered to express a GD2-specific antigen receptor display built-in ADCC-
like activity against tumour cells of neuroectodermal origin. J Cell Mol Med
(2012) 16(3):569–81. doi:10.1111/j.1582-4934.2011.01343.x
55. Chang Y-H, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A
chimeric receptor with NKG2D specificity enhances natural killer cell activa-
tion and killing of tumor cells. Cancer Res (2013) 73(6):1777–86. doi:10.1158/
0008-5472.CAN-12-3558
56. Goding SR, Yang Q, Knudsen KB, Potter DM, Basse PH. Cytokine gene therapy
using adenovirally transduced, tumor-seeking activated natural killer cells.
Hum Gene Ther (2007) 18(8):701–11. doi:10.1089/hum.2007.052
57. Nagashima S, Mailliard R, Kashii Y, Reichert TE, Herberman RB, Robbins P,
et al. Stable transduction of the interleukin-2 gene into human natural killer cell
lines and their phenotypic and functional characterization in vitro and in vivo.
Blood (1998) 91(10):3850–61.
58. Vujanovic NL, Yasumura S, Hirabayashi H, Lin W, Watkins S, Herberman RB,
et al. Antitumor activities of subsets of human IL-2-activated natural killer cells
in solid tissues. J Immunol (1995) 154(1):281–9.
59. Goding S, Yang Q, Mi Z, Robbins P, Basse P. Targeting of products of genes to
tumor sites using adoptively transferred A-NK and T-LAK cells. Cancer Gene
Ther (2007) 14(5):441–50. doi:10.1038/sj.cgt.7701019
60. CooperMA, Bush JE, Fehniger TA, VanDeusen JB,Waite RE, Liu Y, et al. In vivo
evidence for a dependence on interleukin 15 for survival of natural killer cells.
Blood (2002) 100(10):3633–8. doi:10.1182/blood-2001-12-0293
61. Ranson T, Vosshenrich CA, Corcuff E, Richard O, Müller W, Di Santo JP. IL-
15 is an essential mediator of peripheral NK-cell homeostasis. Blood (2003)
101(12):4887–93. doi:10.1182/blood-2002-11-3392
62. Jiang W, Zhang J, Tian Z. Functional characterization of interleukin-15 gene
transduction into the human natural killer cell line NKL. Cytotherapy (2008)
10(3):265–74. doi:10.1080/14653240801965156
63. Leung W-H, Vong QP, Lin W, Janke L, Chen T, Leung W. Modulation
of NKG2D ligand expression and metastasis in tumors by spironolactone
via RXRγ activation. J Exp Med (2013) 210(12):2675–92. doi:10.1084/jem.
20122292
64. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Ødum N. Cancer
cells become susceptible to natural killer cell killing after exposure to histone
deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression
of MHC class I-related chain A and B. Cancer Res (2005) 65(23):11136–45.
doi:10.1158/0008-5472.CAN-05-0599
65. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U,
Langenkamp U, et al. NKG2D ligand expression in AML increases in response
to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell
lines with single KIR-HLA class I specificities. Blood (2008) 111(3):1428–36.
doi:10.1182/blood-2007-07-101311
66. Wennerberg E, Sarhan D, Carlsten M, Kaminskyy VO, D’Arcy P, Zhivo-
tovsky B, et al. Doxorubicin sensitizes human tumor cells to NK cell- and
T-cell-mediated killing by augmented TRAIL receptor signaling. Int J Cancer
(2013) 133(7):1643–52. doi:10.1002/ijc.28163
67. Borg C, Terme M, Taïeb J, Ménard C, Flament C, Robert C, et al. Novel
mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent
antitumor effects. J Clin Invest (2004) 114(3):379. doi:10.1172/JCI200421102
68. Bellucci R, Nguyen H-N, Martin A, Heinrichs S, Schinzel AC, Hahn WC, et al.
Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.
J Clin Invest (2012) 122(7):2369. doi:10.1172/JCI58457
69. Krusch M, Salih J, Schlicke M, Baessler T, Kampa KM, Mayer F, et al. The
kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor
reactivity in vitro. J Immunol (2009) 183(12):8286–94. doi:10.4049/jimmunol.
0902404
70. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. Lenalidomide
enhances natural killer cell andmonocyte-mediated antibody-dependent cellu-
lar cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res (2008)
14(14):4650–7. doi:10.1158/1078-0432.CCR-07-4405
71. Hallett WH, Ames E, Álvarez M, Barao I, Taylor PA, Blazar BR, et al. Com-
bination therapy using IL-2 and anti-CD25 results in augmented natural
killer cell-mediated antitumor responses. Biol Blood Marrow Transplant (2008)
14(10):1088–99. doi:10.1016/j.bbmt.2008.08.001
72. Bae S,OhK,KimH,KimY,KimH-R,HwangY-I, et al. The effect of alloferon on
the enhancement of NK cell cytotoxicity against cancer via the up-regulation of
perforin/granzyme B secretion. Immunobiology (2013) 218(8):1026–33. doi:10.
1016/j.imbio.2012.12.002
73. James AM, Cohen AD, Campbell KS. Combination immune therapies to
enhance anti-tumor responses by NK cells. Front Immunol (2013) 4:481. doi:10.
3389/fimmu.2013.00481
74. Moreau P, editor. The future of therapy for relapsed/refractory multiple
myeloma: emerging agents and novel treatment strategies. Semin Hematol
(2012) 49(Suppl 1):S3346. doi:10.1053/j.seminhematol.2012.05.004
75. Benson DM, Byrd JC. CS1-directed monoclonal antibody therapy for multiple
myeloma. J Clin Oncol (2012) 30(16):2013–5. doi:10.1200/JCO.2011.40.4061
76. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, et al.
Stimulation of natural killer cells with a CD137-specific antibody enhances
trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest
(2012) 122(3):1066–75. doi:10.1172/JCI61226
77. Buechele C, Baessler T, Schmiedel BJ, Schumacher CE, Grosse-Hovest L, Rittig
K, et al. 4-1BB ligand modulates direct and rituximab-induced NK-cell reac-
tivity in chronic lymphocytic leukemia. Eur J Immunol (2012) 42(3):737–48.
doi:10.1002/eji.201141920
78. Buechele C, Baessler T, Wirths S, Schmohl J, Schmiedel B, Salih H.
Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates
cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL).
Leukemia (2012) 26(5):991–1000. doi:10.1038/leu.2011.313
79. Schmiedel BJ, Werner A, Steinbacher J, Nuebling T, Buechele C, Grosse-Hovest
L, et al. Generation and preclinical characterization of a Fc-optimized GITR-Ig
fusion protein for induction of NK cell reactivity against leukemia. Mol Ther
(2013) 21(4):877–86. doi:10.1038/mt.2013.11
80. Vey N, Bourhis J-H, Boissel N, Bordessoule D, Prebet T, Charbonnier A, et al.
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete
remission. Blood (2012) 120(22):4317–23. doi:10.1182/blood-2012-06-437558
81. Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath
S, Abonour R, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients
with relapsed/refractory multiple myeloma. Blood (2012) 120(22):4324–33.
doi:10.1182/blood-2012-06-438028
82. Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, et al. Anti-
KIR antibody enhancement of anti-lymphoma activity of natural killer cells
as monotherapy and in combination with anti-CD20 antibodies. Blood (2014)
123(5):678–86. doi:10.1182/blood-2013-08-519199
83. BensonDM Jr, BakanCE,Mishra A,Hofmeister CC, Efebera Y, Becknell B, et al.
The PD-1/PD-L1 axis modulates the natural killer cell versusmultiple myeloma
effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
Blood (2010) 116(13):2286–94. doi:10.1182/blood-2010-02-271874
84. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA,
et al. Durable cancer regression off-treatment and effective reinduction therapy
with an anti-PD-1 antibody. Clin Cancer Res (2013) 19(2):462–8. doi:10.1158/
1078-0432.CCR-12-2625
85. Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM.
Blocking NK cell inhibitory self-recognition promotes antibody-dependent
Frontiers in Immunology | www.frontiersin.org June 2015 | Volume 6 | Article 2867
Lim et al. Allogeneic NK cell therapy
cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol (2008)
180(9):6392–401. doi:10.4049/jimmunol.180.9.6392
86. Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX,
et al. Bispecific and trispecific killer cell engagers directly activate human
NK cells through CD16 signaling and induce cytotoxicity and cytokine pro-
duction. Mol Cancer Ther (2012) 11(12):2674–84. doi:10.1158/1535-7163.
MCT-12-0692
87. Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, et al.
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against pri-
mary MDS and MDSC CD33+ targets. Blood (2014) 123(19):3016–26. doi:10.
1182/blood-2013-10-533398
Conflict of Interest Statement: Yu Kyeong Hwang is a current employee of Green-
Cross LabCell. The other co-authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2015 Lim, Jung, Hwang and Shin. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org June 2015 | Volume 6 | Article 2868
